Y0002407

Brivaracetam CRS

European Pharmacopoeia (EP) Reference Standard

• 同義詞: Brivaracetam, (αS,4R)-α-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide, (2S)-2-[(4R)-2-Oxo-4-propylpyrrolidin-1-yl]butanamide, (S)-2-((R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide, UCB 34714, UCB-34714, UCB34714
• 經驗公式（希爾表示法）: C₁₁H₂₀N₂O₂
• CAS號碼: 357336-20-0
• 分子量：: 212.29
• MDL號碼: MFCD25976668
• 分類程式碼代碼: 41116107
• 分類程式碼代碼: 12352200
• NACRES: NA.24

屬性

• 等級: pharmaceutical primary standard
• 製造商／商標名: EDQM
• 應用: pharmaceutical
• 儲存溫度: 2-8°C

描述

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. Compendial materials should be used for the purpose described in the appropriate monograph unless otherwise authorized by the National Competent Authority. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

e.g. pharmaceutical (small molecule)

生化／生理作用

Brivaracetam shows approximately 10 times greater potency than levetiracetam (Keppra)*; pIC50 at LBS = 7.0; inhibits audiogenic seizures in seizure-prone mice (ED50 = 14 μmol/kg) and is also effective in other animal models of epilepsy. Brivaracetam is used as an anticonvulsant (antiepileptic) for seizure treatment.

Orally active levetiracetam analog with higher synaptic vesicle protein 2A (SV2A) affinity and >10 times greater in vivo antiseizure efficay.

包裝

Unit quantity: 160mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

安全資訊

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable